45.85
2.99%
+1.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Merus N.V Borsa (MRUS) Ultime notizie
Merus gibt Finanzergebnisse für das erste Quartal 2024 bekannt und informiert über den aktuellen Geschäftsverlauf
GlobeNewswire Inc.
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire Inc.
Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
Zacks Investment Research
Merus annonce l’acceptation par la FDA américaine et l’examen prioritaire de la demande de licence de produit biologique relative à Zeno dans le traitement du CPNPC et de l’ACP NRG1+
GlobeNewswire Inc.
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
GlobeNewswire Inc.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Zacks Investment Research
Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO
GlobeNewswire Inc.
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
GlobeNewswire Inc.
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
GlobeNewswire Inc.
Merus participera à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare
GlobeNewswire Inc.
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Zacks Investment Research
Merus kündigt die Veröffentlichung eines Abstracts für die Präsentation auf der Jahrestagung 2024 der AACR an: Zeno hat sich in Krebsmodellen mit hoher NRG1-Expression als wirksam erwiesen
GlobeNewswire Inc.
Merus annonce ses résultats financiers pour le quatrième trimestre 2023 ainsi que pour l’ensemble de l’exercice 2023 et fait le point sur ses activités
GlobeNewswire Inc.
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
GlobeNewswire Inc.
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Merus nimmt an bevorstehenden Investorenkonferenzen teil
GlobeNewswire Inc.
Merus to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?
Zacks Investment Research
Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?
Zacks Investment Research
Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?
Zacks Investment Research
Biotech stocks set for a rebound in 2024, analysts say
MarketWatch
Biotech stocks set for a rebound in 2024, analysts say
MarketWatch
Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet
Zacks Investment Research
Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
Merus präsentiert Zwischenergebnisse zu MCLA-129 auf dem ESMO Asia Congress 2023
GlobeNewswire Inc.
Expert Ratings for Merus
Benzinga
Merus annonce la publication de résumés sur le MCLA-129 à présenter lors de l’édition 2023 du congrès ESMO Asia
GlobeNewswire Inc.
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
GlobeNewswire Inc.
Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?
Zacks Investment Research
Capitalizzazione:
|
Volume (24 ore):